Zai Lab

Zai Lab FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Zai Lab (ZLAB) as of Nov 22, 2026 is 93.55 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 107.50 % — a change of -12.98% (lower).

FCF Conversion

93.55 %

YoY

-12.98%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Zai Lab is 2025 93.55 % . FCF Conversion Rate (FCF/EBITDA) of Zai Lab was 2024 107.50 % . It decreases by -12.98% lower compared to the previous year.

The Zai Lab FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
77.41 USD
Jan 1, 2019
112.48 USD
Jan 1, 2020
84.31 USD
Jan 1, 2021
80.65 USD
Jan 1, 2022
88.57 USD
Jan 1, 2023
61.76 USD
Jan 1, 2024
107.50 USD
Jan 1, 2025
93.55 USD
The Zai Lab FCF Conversion history
YEARFCF ConversionYoY
93.55 %-12.98%
107.50 %+74.06%
61.76 %-30.27%
88.57 %+9.82%
80.65 %-4.34%
84.31 %-25.04%
112.48 %+45.31%
77.41 %-5.98%
82.34 %-10.18%
91.67 %+35.38%
67.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd, based in Pudong, China, is a biopharmaceutical company operating in the Health Care sector. It develops and commercializes innovative treatments for oncology, immunology, neuroscience, and infectious diseases. The company offers products such as Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, Optune for brain tumors, Qinlock for gastrointestinal tumors, Xacduro for bacterial pneumonia, and Augtyro for lung cancer. Zai Lab collaborates with leading pharmaceutical firms including Pfizer and Amgen. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

FCF Conversion Rate (FCF/EBITDA) of Zai Lab is 93.55 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Zai Lab changed from 107.50 % to 93.55 %, representing a -12.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Zai Lab since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Zai Lab with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Zai Lab

All Key Metrics — Zai Lab